by Paul Sharpe and Tom Keelin
In this paper, former SDG consultant Tom Keelin and Paul Sharpe of then-SmithKline Beecham detail the portfolio management process SDG developed to maximize the value of SmithKline Beecham’s drug research & development portfolio. This work required a transformation in SmithKline Beecham’s analytic and organizational processes and has been an HBR best-seller since its publication.
Published in 1998 in the Harvard Business Review. The article is available at this link.